Yahoo Suche Web Suche

Anmelden

Suchergebnisse

  1. Suchergebnisse:

  1. www.aps-hh.de › grosshandelGroßhandel - antares-Klinikversorgung

    8. Nov. 2023 · Mit der GDP-Zertifizierung (GDP = Good Distribution Practices) bieten wir gesicherte Qualität und sind verlässlicher Partner in der Lieferkette des Gesundheitswesens. Gute Vertriebspraxis ist antares pharma service im gesamten Prozess wichtig, von der sach- und fachgerechten Lagerung, dem Transport und der Anlieferung von Arzneimitteln.

  2. www.onvista.de › aktien › ANTARES-PHARMA-Aktie-US0366421065ANTARES PHARMA Aktie (903128 | US0366421065) • onvista

    Realtime Aktienkurs der ANTARES PHARMA Aktie mit Live-Chart inkl. Kursentwicklung, News & Analysen. Aktueller Aktienwert heute inkl. Aktienverlauf & Wertentwicklung.

  3. www.linkedin.com › company › antares-pharma-inc-Antares Pharma Inc. | LinkedIn

    Antares Pharma Inc. | 5,146 followers on LinkedIn. Making Medicines Feel Better | About Antares Antares Pharma is a specialty pharmaceutical company that combines drug development expertise with ...

  4. www.marketwatch.com › story › antares-pharma-stock-rocketsAntares Pharma stock rockets after Halozyme buyout deal ... -...

    13. Apr. 2022 · Shares of Antares Pharma Inc. atrs rocketed 46.3% in premarket trading Wednesday toward a two-decade high, after the specialty pharmaceutical company agreed to be acquired by Halozyme Therapeutics ...

  5. www.marketscreener.com › quote › stockAntares Pharma, Inc. Stock (ATRS) - Quote Nasdaq- MarketScreener

    Piper Sandler Downgrades Antares Pharma to Neutral From Overweight, Adjusts Price Target to $5.60 From $6. 22-04-14. MT. Raymond James Downgrades Antares Pharma to Market Perform From Strong Buy. 22-04-14. MT. Truist Securities Downgrades Antares Pharma to Hold From Buy, Adjusts PT to $5.60 From $7.00.

  6. finance.yahoo.com › news › halozyme-buys-antares-960m-dealHalozyme Buys Antares In $960M Deal To Create One Drug Delivery...

    13. Apr. 2022 · Halozyme Therapeutics Inc (NASDAQ: HALO) will acquire Antares Pharma Inc (NASDAQ: ATRS) for $5.60 per share, valuing Antares at approximately 0 million. The transaction is expected to be accretive ...

  7. www.marketscreener.com › quote › stockAntares Pharma : Halozyme to Acquire Antares Pharma to Create a...

    13. Apr. 2022 · SAN DIEGO and EWING, N.J., April 13, 2022 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") and Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") today announced that the companies have entered into a definitive agreement pursuant to which Halozyme will acquire Antares for $5.60 per share in cash. The transaction, which values Antares at approximately $960 million, was unanimously ...